| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
|
Medicine details |
|
| Medicine name | dostarlimab (Jemperli®) |
| Formulation | 500 mg concentrate for solution for infusion |
| Reference number | 4406 |
| Indication | Monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum‑containing regimen |
| Company | GlaxoSmithKline UK |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/03/2021 |
| NICE guidance | |